INAB Projected Dividend Yield
IN8bio Inc ( NASDAQ : INAB )IN8bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Co.'s lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). 21 YEAR PERFORMANCE RESULTS |
INAB Dividend History Detail INAB Dividend News INAB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |